Beta-nicotinamide mononucleotide

• Catalog Number: ACM1094617
• Product Name: Beta-nicotinamide mononucleotide
• CAS: 1094-61-7
• Category: Main Products
• Synonyms: BETA-NMN;BETA-NICOTINAMIDE MONONUCLEOTIDE;BETA-NICOTINAMIDE RIBOSE MONOPHOSPHATE;NMN;NICOTINAMIDE-1-IUM-1-BETA-D-RIBOFURANOSIDE 5-PHOSPHATE;NICOTINAMIDE RIBOTIDE;NICOTINAMIDE MONONUCLEOTIDE;3-(aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium
• IUPAC Name: NMN zwitterion
• Molecular Weight: 334.22
• Molecular Formula: C₁₁H₁₅N₂O₈P
• Appearance: white powder
• Exact Mass: 334.05700

Case Study

Exploration of Various Therapeutic Applications of Nicotinamide Mononucleotide

Poddar, Saikat Kumar, et al. Biomolecules, 2019, 9(1), 34.

Nicotinamide mononucleotide (NMN) is a nicotinamide adenine dinucleotide (NAD+) biosynthetic intermediate. The NMN molecule has demonstrated multiple beneficial pharmacological activities in preclinical studies, meaning it may have therapeutic uses in a variety of fields. Most of the pharmacological effects of NMN occur by promoting NAD+ synthesis.
Pharmacological activities and uses of nicotinamide mononucleotide
· Ischemia-reperfusion injury: NMN has the ability to activate SIRT1, thereby imitating the effect of IPC to improve ischemia-reperfusion injury.
· Neurological disorders: NMN can treat the underlying causes of Alzheimer's disease, such as abnormal mitochondrial morphology, reduced oxygen consumption rate (OCR) and NAD+ levels. A study on a mouse model of collagenase-induced ICH showed that NMN can improve intracerebral hemorrhage (ICH).
· Diabetes: NMN may improve insulin resistance, a characteristic of type 2 diabetes, by increasing NAD+.
· Obesity and its related complications: NMN can reduce age-related weight gain in a dose-dependent manner, which is supported by mouse studies.
· Aging: As one of the precursors of NAD+, NMN is thought to have beneficial effects in inducing neurogenesis, preventing melanocyte stem cell depletion, and slightly extending the lifespan of mice.

The Efficacy and Safety of Beta-Nicotinamide Mononucleotide Supplementation

Yi, Lin, et al. Geroscience, 2023, 45(1), 29-43.

Studies involving animals found that supplementing with beta-nicotinamide mononucleotide (NMN) caused an increase in nicotinamide adenine dinucleotide (NAD) levels, leading to an extension of both healthspan and lifespan. To determine if these positive outcomes could also apply to humans, a double-blind clinical trial was carried out at multiple centers using varying doses of NMN. Results indicate that NMN supplementation increases blood NAD concentrations and that daily oral doses of up to 900 mg NMN are safe and well tolerated.
Experimental procedures for evaluating β-nicotinamide mononucleotide
· Blinding was performed by packaging NMN or placebo capsules into opaque bottles, all of which were identically labeled "NMN or placebo" and placed in a coding suite.
· 80 participants were randomly divided into 4 groups, taking placebo, 300 mg, 600 mg and 900 mg NMN respectively, with 20 participants in each group.
· Participants were assigned these coded kits and instructed to take 2/4/6 capsules corresponding to 300/600/900 mg NMN or placebo, respectively. Neither participants nor trialists knew which of the bottles was NMN or placebo, thus ensuring double blinding.
· Evaluation of the efficacy and safety of NMN involves blood NAD concentration assessment, six-minute walk test, blood biological age test, etc.